Mineralys Therapeutics, Inc./$MLYS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Ticker

$MLYS
Primary listing

Industry

Biotechnology

Employees

51

ISIN

US6031701013

MLYS Metrics

BasicAdvanced
$937M
-
-$3.73
-0.18
-

Bulls say / Bears say

Lorundrostat demonstrated significant efficacy in the Launch-HTN trial, achieving a 16.9 mmHg reduction in systolic blood pressure at week 6, with a 9.1 mmHg placebo-adjusted reduction (p<0.0001), and further improvements at week 12 with a 19.0 mmHg reduction. (stocktitan.net)
The Advance-HTN trial results were presented at the American College of Cardiology’s ACC.25 meeting and published in the New England Journal of Medicine, highlighting lorundrostat's potential as a transformative treatment for uncontrolled or resistant hypertension. (nasdaq.com)
Mineralys completed a public equity financing of approximately $201.2 million in March 2025, bolstering its cash reserves to $343.0 million as of March 31, 2025, expected to fund operations into 2027. (nasdaq.com)
Mineralys reported a net loss of $42.2 million for Q1 2025, an increase from $31.5 million in Q1 2024, primarily due to rising research and development expenses. (nasdaq.com)
The company launched a $250 million public offering of common stock in March 2025, which could lead to shareholder dilution. (investing.com)
Pomerantz LLP announced an investigation into claims on behalf of investors of Mineralys Therapeutics, raising concerns about potential securities fraud or other unlawful business practices. (prnewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MLYS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs